Pelosi to urge House to pass Biden inflation-reduction bill as is
Reuters
Published Aug 09, 2022 08:01AM ET
Updated Aug 09, 2022 08:41AM ET
WASHINGTON (Reuters) -House Speaker Nancy Pelosi said on Tuesday she will ask members of the House of Representatives to pass without changes a $430 billion climate and prescription drug bill approved by U.S. Senate over the weekend, calling it a historic piece of legislation.
Asked if she would ask lawmakers to pass the sweeping legislation as is, Pelosi said "yes."
"Our members are very pleased," Pelosi told NBC's "Today" show. "Quite a bit of what is in the bill is what we had worked (on) together - the House and Senate - to do."
The bill's provisions on prescription drug costs were "historic", she said, and welcomed its climate change initiatives.
The U.S. Senate on Sunday passed the $430 billion bill intended to fight climate change, lower drug prices and raise some corporate taxes in a major victory for President Joe Biden that Democrats hope will aid their chances of keeping control of Congress in this year's elections.
After a marathon, 27-hour weekend session of debate and Republican efforts to derail the package, the Senate approved the Inflation Reduction Act by a 51-50 party line vote.
The action sends the measure to the House of Representatives for a vote, likely on Friday when representatives plan to reconvene briefly during a summer recess. They are expected to pass it, which would then send the bill to the White House for Biden's signature. In a statement, Biden said he looked forward to signing the bill into law.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.